Advertisement

Current Genetic Medicine Reports

, Volume 6, Issue 2, pp 43–51 | Cite as

Patient Care Situations Benefiting from Pharmacogenomic Testing

  • Rachel A. Mills
  • Jennifer N. Eichmeyer
  • Leah M. Williams
  • Julie A. Muskett
  • Tara J. Schmidlen
  • Kristin A. Maloney
  • Amy A. Lemke
Genetic Counseling and Clinical Testing (B LeRoy and N Callanan, Section Editors)
Part of the following topical collections:
  1. Genetic Counseling and Clinical Testing

Abstract

Purpose of Review

Pharmacogenomics is an evolving area in precision medicine that aims to identify patients who have variable drug response, detect those at risk for developing adverse events, and guide drug dosing. Guidelines for optimization of PGx testing are available for a number of drug-gene pairs, and evidence supporting the clinical utility of this service is growing in specific patient contexts. This report reviews a variety of patient care situations in which evidence is emerging to show patient benefit from pharmacogenomic (PGx) testing.

Recent Findings

Preemptive PGx testing minimizes delays in treatment, reducing costs and time to therapeutic effect; however, preemptive testing is currently not feasible in all healthcare settings. Therefore, specific patient care situations that could benefit from PGx testing to be prioritized include medications requiring PGx testing, adverse drug reactions, therapeutic failures, polypharmacy, special populations, and specialty care settings such as cardiology, oncology, and psychiatry.

Summary

Although preemptive PGx testing is likely the best option for patient care, implementation challenges are impeding its uptake. PGx testing is beneficial and more feasible in certain patient situations and may be a starting point for implementation of PGx testing in a care setting. Continued efforts to evaluate patient and provider use and outcomes of PGx testing services will be helpful in informing the current evidence base and standard of care.

Keywords

Pharmacogenomics Pharmacogenetics PGx Pharmacogenetic testing Patient care 

Notes

Acknowledgements

The authors would like to thank members of the National Society of Genetic Counselors Precision Medicine SIG Pharmacogenetics Working Group as well as Dr. Deepak Voora and Dr. Susanne Haga for their thoughtful comments on manuscript drafts.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Collins SL, Carr DF, Pirmohamed M. Advances in the pharmacogenomics of adverse drug reactions. Drug Saf. 2016;39(1):15–27.  https://doi.org/10.1007/s40264-015-0367-8. This review provides a history of pharmacogenetic discovery and the genetic impact on adverse drug reactions. PubMedCrossRefGoogle Scholar
  2. 2.
    Chang MT, McCarthy JJ, Shin J. Clinical application of pharmacogenetics: focusing on practical issues. Pharmacogenomics. 2015;16(15):1733–41.  https://doi.org/10.2217/pgs.15.112.PubMedCrossRefGoogle Scholar
  3. 3.
    FDA. Table of pharmacogenomic biomarkers in drug labels. https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm. 2017;Last updated October 3, 2017(Accessed January 5, 2018).
  4. 4.
    Whirl-Carrillo M, McDonagh EM, Herbert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–7.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91(4):734–8.  https://doi.org/10.1038/clpt.2011.355.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153–8.  https://doi.org/10.1038/clpt.2012.209.PubMedCrossRefGoogle Scholar
  7. 7.
    Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37–44.  https://doi.org/10.1002/cpt.597.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2016;99(4):363–9.  https://doi.org/10.1002/cpt.269.PubMedCrossRefGoogle Scholar
  9. 9.
    Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–34.  https://doi.org/10.1002/cpt.147.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–23.  https://doi.org/10.1038/clpt.2013.105.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376–82.  https://doi.org/10.1038/clpt.2013.254.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96(4):423–8.  https://doi.org/10.1038/clpt.2014.125.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19–24.  https://doi.org/10.1002/cpt.113.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014;96(5):542–8.  https://doi.org/10.1038/clpt.2014.159.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017;2016  https://doi.org/10.1002/cpt.583.
  16. 16.
    Muir AJ, Gong L, Johnson SG, Lee MT, Williams MS, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens. Clin Pharmacol Ther. 2014;95(2):141–6.  https://doi.org/10.1038/clpt.2013.203.PubMedCrossRefGoogle Scholar
  17. 17.
    Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther. 2014;96(2):169–74.  https://doi.org/10.1038/clpt.2014.97.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210–6.  https://doi.org/10.1002/cpt.911.PubMedCrossRefGoogle Scholar
  19. 19.
    Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213–8.  https://doi.org/10.1002/cpt.598.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Clancy JP, Johnson SG, Yee SW, McDonagh EM, Caudle KE, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther. 2014;95(6):592–7.  https://doi.org/10.1038/clpt.2014.54.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102:397–404.  https://doi.org/10.1002/cpt.668.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Leckband SG, Kelsoe JR, Dunnenberger HM, George AL Jr, Tran E, Berger R, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013;94(3):324–8.  https://doi.org/10.1038/clpt.2013.103. PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89(3):387–91.  https://doi.org/10.1038/clpt.2010.320.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin Pharmacol Ther. 2014;95(5):499–500.  https://doi.org/10.1038/clpt.2014.38.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36–7.  https://doi.org/10.1002/cpt.161.PubMedCrossRefGoogle Scholar
  26. 26.
    Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013;93(4):324–5.  https://doi.org/10.1038/clpt.2013.4.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    •• Relling MV, Klein TECPIC. Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89(3):464–7.  https://doi.org/10.1038/clpt.2010.279. This article describes the rationale for forming the CPIC and an overview of how CPIC develps guidelines. PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    •• Clinical Pharmacogenetics Implementation Consortium. CPIC Guidelines. 2018. http://cpicpgx.org/guidelines/. This website provides all CPIC guidelines and updates to guidelines.
  29. 29.
    Weitzel KW, Cavallari LH, Lesko LJ. Preemptive panel-based pharmacogenetic testing: the time is now. Pharm Res. 2017;34(8):1551–5.  https://doi.org/10.1007/s11095-017-2163-x.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn. 2016;18(3):438–45.  https://doi.org/10.1016/j.jmoldx.2016.01.003.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther. 2012;92(2):235–42.  https://doi.org/10.1038/clpt.2012.66.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    •• Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55:89–106.  https://doi.org/10.1146/annurev-pharmtox-010814-124835. This provides an overview of programs providing pre-emptive pharmacogenetic testing including barriers, details of implementation process, and resources. PubMedCrossRefGoogle Scholar
  33. 33.
    Borobia AM, Dapia I, Tong HY, Arias P, Munoz M, Tenorio J, et al. Clinical implementation of pharmacogenetic testing in a hospital of the Spanish National Health System: strategy and experience over 3 years. Clin Transl Sci. 2017;11:189–99.  https://doi.org/10.1111/cts.12526.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Janssens AC, Deverka PA. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing. Clin Pharmacol Ther. 2014;96(6):652–4.  https://doi.org/10.1038/clpt.2014.186.PubMedCrossRefGoogle Scholar
  35. 35.
    Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013;15(4):258–67.  https://doi.org/10.1038/gim.2012.157.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther. 2013;94(2):207–10.  https://doi.org/10.1038/clpt.2013.59.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clin Pharmacol Ther. 2017;102(3):502–10.  https://doi.org/10.1002/cpt.630.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Tonk ECM, Gurwitz D, Maitland-van der Zee AH, Janssens A. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J. 2017;17(4):386–92.  https://doi.org/10.1038/tpj.2016.34.PubMedCrossRefGoogle Scholar
  39. 39.
    • Peterson JF, Bowton E, Field JR, Beller M, Mitchell J, Schildcrout J, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med. 2013;15(10):833–41.  https://doi.org/10.1038/gim.2013.109. This study examined the design and implementation of electronic health record support for a pharmacogenomics panel test. PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    • Haga SB, Moaddeb J. Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenet Genomics. 2014;24(3):139–45.  https://doi.org/10.1097/FPC.0000000000000028. This review considers the benefits and limitations of pre-emptive and point-of-care delivery of pharmacogenetic testing. PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Lemke AA, Hutten Selkirk CG, Glaser NS, Sereika AW, Wake DT, Hulick PJ, et al. Primary care physician experiences with integrated pharmacogenomic testing in a community health system. Personalized Medicine. 2017;14(5):389–400.PubMedCrossRefGoogle Scholar
  42. 42.
    • O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, et al. Pharmacogenomics-based point-of-care clinical decision support significantly alters drug prescribing. Clin Pharmacol Ther. 2017;102(5):859–69.  https://doi.org/10.1002/cpt.709. This study found that utilization of a clinical support system to guide care based on pre-emptive pharmacogenetic testing improved prescribing and reduced patient risk. PubMedCrossRefGoogle Scholar
  43. 43.
    Freimuth RR, Formea CM, Hoffman JM, Matey E, Peterson JF, Boyce RD. Implementing genomic clinical decision support for drug-based precision medicine. CPT Pharmacometrics Syst Pharmacol. 2017;6(3):153–5.  https://doi.org/10.1002/psp4.12173.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O'Neill C, et al. Implementation of pharmacogenetics: the University of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet C Semin Med Genet. 2014;166(1):76–84.  https://doi.org/10.1002/ajmg.c.31396.CrossRefGoogle Scholar
  45. 45.
    Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92(1):87–95.  https://doi.org/10.1038/clpt.2011.371.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    • Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, Pulley J, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95(4):423–31.  https://doi.org/10.1038/clpt.2013.229. This study identified one or more actionable pharmacogenetic variants in 91% of participants, highlighting a potential advantage of preemptive testing. PubMedCrossRefGoogle Scholar
  47. 47.
    Johnson JA, Elsey AR, Clare-Salzler MJ, Nessl D, Conlon M, Nelson DR. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics. 2013;14(7):723–6.  https://doi.org/10.2217/pgs.13.59.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012;92(4):446–9.  https://doi.org/10.1038/clpt.2012.117.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    O'Donnell PH, Danahey K, Jacobs M, Wadhwa NR, Yuen S, Bush A, et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care—initial results of the University of Chicago “1,200 Patients Project”. Am J Med Genet C Semin Med Genet. 2014;166C(1):68–75.  https://doi.org/10.1002/ajmg.c.31385. PubMedCrossRefGoogle Scholar
  50. 50.
    Pierson RC, Gufford BT, Desta Z, Eadon MT. Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial. Pharmacogenomics. 2017;18(9):835–41.  https://doi.org/10.2217/pgs-2017-0042.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Cavallari LH, Weitzel KW, Elsey AR, Liu X, Mosley SA, Smith DM, et al. Institutional profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics. 2017;18(5):421–6.  https://doi.org/10.2217/pgs-2017-0028.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, et al. The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real-world setting. Clin Transl Sci. 2017;10(3):143–6.  https://doi.org/10.1111/cts.12456.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Rasmussen-Torvik LJ, Stallings SC, Gordon AS, Almoguera B, Basford MA, Bielinski SJ, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014;96(4):482–9.  https://doi.org/10.1038/clpt.2014.137.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Bush WS, Crosslin DR, Owusu-Obeng A, Wallace J, Almoguera B, Basford MA, et al. Genetic variation among 82 pharmacogenes: the PGRNseq data from the eMERGE network. Clin Pharmacol Ther. 2016;100(2):160–9.  https://doi.org/10.1002/cpt.350.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Rohrer Vitek CR, Abul-Husn NS, Connolly JJ, Hartzler AL, Kitchner T, Peterson JF, et al. Healthcare provider education to support integration of pharmacogenomics in practice: the eMERGE Network experience. Pharmacogenomics. 2017;18(10):1013–25.  https://doi.org/10.2217/pgs-2017-0038.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Bielinski SJ, Olson JE, Pathak J, Weinshilboum RM, Wang L, Lyke KJ, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014;89(1):25–33.  https://doi.org/10.1016/j.mayocp.2013.10.021.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Scott SA, Owusu Obeng A, Botton MR, Yang Y, Scott ER, Ellis SB, et al. Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. Pharmacogenomics. 2017;18(15):1381–6.  https://doi.org/10.2217/pgs-2017-0137.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Olson JE, Rohrer Vitek CR, Bell EJ, McGree ME, Jacobson DJ, St Sauver JL, et al. Participant-perceived understanding and perspectives on pharmacogenomics: the Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time). Genet Med. 2017;19:819–25.  https://doi.org/10.1038/gim.2016.192.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Gottesman O, Scott SA, Ellis SB, Overby CL, Ludtke A, Hulot JS, et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin Pharmacol Ther. 2013;94(2):214–7.  https://doi.org/10.1038/clpt.2013.72.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Crosslin DR, Robertson PD, Carrell DS, Gordon AS, Hanna DS, Burt A, et al. Prospective participant selection and ranking to maximize actionable pharmacogenetic variants and discovery in the eMERGE Network. Genome Med. 2015;7(1):67.  https://doi.org/10.1186/s13073-015-0181-z.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    • Dickmann LJ, Ware JA. Pharmacogenomics in the age of personalized medicine. Drug Discov Today Technol. 2016;21–22:11–6.  https://doi.org/10.1016/j.ddtec.2016.11.003. This review addresses the current uses of pharmacogenetic information in drug labels, presents case studies on utilizing pharmacogenomics for drug discovery, and identifies challenges in clinical implementation of pharmacogenomic testing. PubMedCrossRefGoogle Scholar
  62. 62.
    PharmGKB. Drug label information and legend. https://www.pharmgkb.org/page/drugLabelLegend. Accessed January 15, 2018.
  63. 63.
    Tangamornsuksan W, Lohitnavy O, Kongkaew C, Chaiyakunapruk N, Reisfeld B, Scholfield NC, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18(1):68–76.PubMedCrossRefGoogle Scholar
  64. 64.
    Sousa-Pinto B, Pinto-Ramos J, Correia C, Goncalves-Costa G, Gomes L, Gil-Mata S, et al. Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01. J Allergy Clin Immunol. 2015;136(4):1092–4 e3.  https://doi.org/10.1016/j.jaci.2015.03.019.PubMedCrossRefGoogle Scholar
  65. 65.
    • Cavallari LH, Weitzel K. Pharmacogenomics in cardiology—genetics and drug response: 10 years of progress. Futur Cardiol. 2015;11(3):281–6.  https://doi.org/10.2217/fca.15.20. This review focuses on the current state of cardiovascular pharmacogenomics including CYP2C19 and clopidogrel, CYP2C9/VKORC1 and warfarin, and SLCO1B1 and simvastatin. CrossRefGoogle Scholar
  66. 66.
    De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684–98.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8.  https://doi.org/10.1093/eurheartj/eht295.PubMedCrossRefGoogle Scholar
  68. 68.
    Charland SL, Agatep BC, Epstein RS, Frueh FW, Herrera V, Devlin J, et al. Patient knowledge of pharmacogenetic information improves adherence to statin therapy: results of the Additional Kif6 Risk Offers Better Adherence to Statins (Akrobats) trial. J Am Coll Cardiol. 2012;59(13):E1848-E.CrossRefGoogle Scholar
  69. 69.
    Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006;62(5):509–11.  https://doi.org/10.1111/j.1365-2125.2006.02806.x.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625–9.  https://doi.org/10.1038/clpt.2011.185.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329–33.  https://doi.org/10.1182/blood-2005-03-1108.PubMedCrossRefGoogle Scholar
  72. 72.
    • Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012;125(16):1997–2005.  https://doi.org/10.1161/CIRCULATIONAHA.111.070920.PubMedCrossRefGoogle Scholar
  73. 73.
    Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–93.  https://doi.org/10.1056/NEJMoa1310669.
  74. 74.
    Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. New Engl J Med. 2013;369(24):2294–303.  https://doi.org/10.1056/Nejmoa1311386.PubMedCrossRefGoogle Scholar
  75. 75.
    •• Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33–41.  https://doi.org/10.1016/j.tcm.2014.09.001. This review provides detailed descriptions of the randomized clinical trials examining genotype-guided dosing of warfarin with conflicting findings, and how they may be interpreted to make care decisions. PubMedCrossRefGoogle Scholar
  76. 76.
    Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA. 2017;318(12):1115–24.  https://doi.org/10.1001/jama.2017.11469.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278–81.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black JL 3rd, Takahashi PY, et al. CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. Pharmgenomics Pers Med. 2017;10:217–27.  https://doi.org/10.2147/PGPM.S136341. PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Wickramage I, Tennekoon KH, Ariyaratne MA, Hewage AS, Sundralingam T. CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study. Breast Cancer (Dove Med Press) 2017;9:111–120. doi: https://doi.org/10.2147/BCTT.S126557.
  80. 80.
    FDA. FDA Drug Safety Communication: reduced effectiveness of plavix (clopidogrel) in patients who are poor metabolizers of the drug. 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed January 15 2018.
  81. 81.
    Cavallari LH. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther. 2017;15(8):581–9.  https://doi.org/10.1080/14779072.2017.1355236.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439–45.  https://doi.org/10.1176/ps.2009.60.11.1439.PubMedCrossRefGoogle Scholar
  83. 83.
    Trivedi MH. Major depressive disorder: remission of associated symptoms. J Clin Psychiatry. 2006;67(Suppl 6):27–32.PubMedGoogle Scholar
  84. 84.
    Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 6):16–25.  https://doi.org/10.4088/JCP.8133su1c.03.PubMedCrossRefGoogle Scholar
  85. 85.
    Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatr. 2010;55(3):126–35.  https://doi.org/10.1177/070674371005500303.CrossRefGoogle Scholar
  86. 86.
    Torrellas C, Carril JC, Cacabelos R. Optimization of antidepressant use with pharmacogenetic strategies. Curr Genomics. 2017;18(5):442–9.  https://doi.org/10.2174/1389202918666170426164940. PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Lazaridis KN. Improving therapeutic odyssey: preemptive pharmacogenomics utility in patient care. Clin Pharmacol Ther. 2017;101(1):39–41.  https://doi.org/10.1002/cpt.543.PubMedCrossRefGoogle Scholar
  88. 88.
    • Wigle TJ, Jansen LE, Teft WA, Kim RB. Pharmacogenomics guided-personalization of warfarin and tamoxifen. J Pers Med. 2017;7(4)  https://doi.org/10.3390/jpm7040020. This paper reviews evidence of the use of pharmacogenomic testing when prescribing warfarin and tamoxifen based on the literature and the authors’ experiences in a personalized medicine program.
  89. 89.
    Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost. 2012;107(2):232–40.  https://doi.org/10.1160/TH11-06-0388.PubMedCrossRefGoogle Scholar
  90. 90.
    Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010;87(5):572–8.  https://doi.org/10.1038/clpt.2010.13.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41.  https://doi.org/10.1016/j.amjopharm.2006.03.002.PubMedCrossRefGoogle Scholar
  92. 92.
    Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013;47(3):324–32.  https://doi.org/10.1345/aph.1R621.PubMedCrossRefGoogle Scholar
  93. 93.
    Pasina L, Brucato AL, Falcone C, Cucchi E, Bresciani A, Sottocorno M, et al. Medication non-adherence among elderly patients newly discharged and receiving polypharmacy. Drugs Aging. 2014;31(4):283–9.  https://doi.org/10.1007/s40266-014-0163-7.PubMedCrossRefGoogle Scholar
  94. 94.
    Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Dir Assoc. 2012;13(9):818 e11–5.  https://doi.org/10.1016/j.jamda.2012.07.019.CrossRefGoogle Scholar
  95. 95.
    Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.  https://doi.org/10.1517/14740338.2013.827660.PubMedCrossRefGoogle Scholar
  96. 96.
    Sugarman EA, Cullors A, Centeno J, Taylor D. Contribution of pharmacogenetic testing to modeled medication change recommendations in a long-term care population with polypharmacy. Drugs Aging. 2016;33(12):929–36.  https://doi.org/10.1007/s40266-016-0412-z.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    • Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016;19(3):213–28.  https://doi.org/10.3111/13696998.2015.1110160. This study found that the use of pharmacogenomic testing and a clinical decision support tool decreased hospitalizations and emergency room visits among eldery patients. PubMedCrossRefGoogle Scholar
  98. 98.
    • Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS One. 2017;12(2):e0170905.  https://doi.org/10.1371/journal.pone.0170905. This prospective study found that pharmacogenetic testing and a clinical decision support tool reduced re-hospitalizations and visits to the emergency department in home health patients. PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Haga SB, Moaddeb J, Mills R, Patel M, Kraus W, Allen LaPointe NM. Incorporation of pharmacogenetic testing into medication therapy management. Pharmacogenomics. 2015;16(17):1931–41.  https://doi.org/10.2217/pgs.15.124.PubMedCrossRefGoogle Scholar
  100. 100.
    Lam MP, Yeung CK, Cheung BM. Pharmacogenetics of allopurinol—making an old drug safer. J Clin Pharmacol. 2013;53(7):675–9.  https://doi.org/10.1002/jcph.67.PubMedCrossRefGoogle Scholar
  101. 101.
    Roberts RL, Stamp LK. Pharmacogenetic considerations in the treatment of gout. Pharmacogenomics. 2015;16(6):619–29.  https://doi.org/10.2217/pgs.15.16.PubMedCrossRefGoogle Scholar
  102. 102.
    Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69–76.  https://doi.org/10.1038/gim.2016.80.PubMedCrossRefGoogle Scholar
  103. 103.
    Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado A, de Andres F, et al. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J. 2016;16(2):113–23.  https://doi.org/10.1038/tpj.2015.70.PubMedCrossRefGoogle Scholar
  104. 104.
    Roden DM. Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet. 2016;61(1):79–85.  https://doi.org/10.1038/jhg.2015.78.PubMedCrossRefGoogle Scholar
  105. 105.
    Bhopalwala AM, Hong RA, Khan ZR, Valentin MR, Badawi RA. Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended. Hawaii J Med Public Health. 2015;74(1):16–20.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Turner RM, Pirmohamed M. Cardiovascular pharmacogenomics: expectations and practical benefits. Clin Pharmacol Ther. 2014;95(3):281–93.  https://doi.org/10.1038/clpt.2013.234.PubMedCrossRefGoogle Scholar
  107. 107.
    • Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessl DR, Obeng AO, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C. 2014;166(1):56–67.  https://doi.org/10.1002/ajmg.c.31390. This study found that successful implementation of genomic medicine benefitted from reducing barriers and utilization of a mutidisciplinary team. CrossRefGoogle Scholar
  108. 108.
    Lieb W, Volzke H, Pulley JM, Roden DM, Kroemer HK. Strategies for personalized medicine-based research and implementation in the clinical workflow. Clin Pharmacol Ther. 2012;92(4):443–5.  https://doi.org/10.1038/clpt.2012.119.PubMedCrossRefGoogle Scholar
  109. 109.
    Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014;32(21):2248–54.  https://doi.org/10.1200/JCO.2013.52.1377.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, et al. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther. 2015;14(6):1488–94.  https://doi.org/10.1158/1535-7163.MCT-14-1061.PubMedCrossRefGoogle Scholar
  111. 111.
    • Hertz DL, Rae J. Pharmacogenetics of cancer drugs. Annu Rev Med. 2015;66:65–81.  https://doi.org/10.1146/annurev-med-053013-053944. This provides an extensive review of pharmacogenes currenty used to guide cancer treatment decisions, and the future potential in genotype-guided cancer treatment. PubMedCrossRefGoogle Scholar
  112. 112.
    Arnall JR, Petro R, Patel JN, Kennedy L. A clinical pharmacy pilot within a precision medicine program for cancer patients and review of related pharmacist clinical practice. J Oncol Pharm Pract 2017:1078155217738324. doi: https://doi.org/10.1177/1078155217738324.
  113. 113.
    Peterson K, Dieperink E, Anderson J, Boundy E, Ferguson L, Helfand M. Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Psychopharmacology. 2017;234(11):1649–61.  https://doi.org/10.1007/s00213-017-4622-9.PubMedCrossRefGoogle Scholar
  114. 114.
    Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. J Clin Psychiatry. 2017;78(6):720–9.  https://doi.org/10.4088/JCP.15r10583.PubMedCrossRefGoogle Scholar
  115. 115.
    Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clin Chem. 2014;60(1):53–9.  https://doi.org/10.1373/clinchem.2013.204446.PubMedCrossRefGoogle Scholar
  116. 116.
    Berm EJ, Looff M, Wilffert B, Boersma C, Annemans L, Vegter S, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One. 2016;11(1):e0146262.  https://doi.org/10.1371/journal.pone.0146262.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    • Fagerness J, Fonseca E, Hess GP, Scott R, Gardner KR, Koffler M, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20(5):e146–56. This retrospective study found that psychiatric patients with genetically guided treatments had increased medication adherence. PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Rachel A. Mills
    • 1
  • Jennifer N. Eichmeyer
    • 2
  • Leah M. Williams
    • 3
  • Julie A. Muskett
    • 4
  • Tara J. Schmidlen
    • 5
  • Kristin A. Maloney
    • 6
  • Amy A. Lemke
    • 7
  1. 1.Department of Medicine, Center for Applied Genomics and Precision MedicineDuke UniversityDurhamUSA
  2. 2.College of Health SciencesBoise State UniversityBoiseUSA
  3. 3.GeneDxGaithersburgUSA
  4. 4.Inova Translational Medicine InstituteFalls ChurchUSA
  5. 5.Genomic Medicine InstituteGeisingerDanvilleUSA
  6. 6.Department of MedicineUniversity of Maryland School of MedicineBaltimoreUSA
  7. 7.Center for Personalized MedicineNorthShore University HealthSystemEvanstonUSA

Personalised recommendations